HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

Brussels, Belgium, {27 April 2004} Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has issued a positive decision for VELCADE, a new treatment for multiple myeloma, a form of blood cancer. The novel drug is indicated to treat multiple myeloma patients who have received at least two prior therapies and demonstrated disease progression on their last therapy.

VELCADE is a completely new approach to treating multiple myeloma that acts on a unique target in cells called the proteasome.

Multiple myeloma is the second most common blood cancer, representing approximately one percent of all cancers and two percent of all cancer deaths. Worldwide in 2000, there were 73,943 cases of multiple myeloma and 57,370 deaths. In Europe there were approximately 19,000 cases in 2000 and just under 15,000 deaths (1). Only 30 percent of multiple myeloma patients survive longer than five years (2).

"The approval of VELCADE by the European Agency for the Evaluation of Medicinal Products (EMEA) represents a breakthrough in our continued battle against multiple myeloma" said Professor Mario Boccadoro, Professor of Hematology, Director of the Section of Hematology, University of Torino, Italy. "With its new and unique mechanism of action, VELCADE represents a new treatment option for patients".

Clinical results from a phase II study have shown that VELCADE can slow, reverse or halt progression of disease in patients who failed on two or more treatments, potentially helping patients live longer. In a study of 202 patients with relapsed and refractory multiple myeloma and who progressed after initial treatments, 35% responded to VELCADE and 10% had a complete remission. This pivotal study was the basis for an accelerated review of VELCADE by U.S. Food and Drug Administration (FDA) and approval within four months of the New Drug Application submission on 13 May 2003.

"We are deli
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:3/27/2015)... According to a recently published report series by ... market in Europe is in decline due to decreasing ... Price decreases are being seen across the entire orthopedic ... total European trauma device market, continued pricing pressure overall ... after year. , “Such price drops are typical ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement ... on and analysis of the healthcare, regulatory and reimbursement ... in 2013 amounted to 316.1 million, having grown at ... 2008. The country’s increasingly elderly population and corresponding increase ... boost the growth of the pharmaceutical market, which was ...
(Date:3/27/2015)... 27, 2015 GrassrootsHealth, an international nonprofit ... Children (POC) NOW! vitamin D demonstration project April 7 ... South Carolina (MUSC), and will soon follow with a ... no cost to a minimum of 500 pregnant women ... these two service areas. The project will include patient ...
(Date:3/27/2015)... March 27, 2015 Trail mix is the ... workout, on weekend hikes and during the game! It’s portable, ... Natural is proud to introduce a new line of specialty ... Deliciously rich and flavorful selections packed with nutritious, 100% all ... fruit and grains that add protein and fiber to your ...
(Date:3/27/2015)... Since September 2014, the country singer has been traveling to ... in retirement for a period of 13 years. Many devoted ... touring, and concert events have been booking quickly in all ... for the two shows recently scheduled for May 8 and ... of discounted Garth Brooks tickets for sale. , The comeback ...
Breaking Medicine News(10 mins):Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
(Date:3/27/2015)... , March 27, 2015 Object recognition technology ... visually impaired and elderly. The VelaSense ® ... to lead more independent, productive and fulfilling lives. VelaSense ... will allow users to identify objects from a one ... as create customized object databases for personal use. ...
(Date:3/27/2015)... - Russell Williams , President of ... 2015-2016 Quebec Budget, noting the fiscal discipline and the ... However, the association is concerned about the decline of ... intent to strive for a balanced budget this year, ... Quebec,s economic development is encouraging," said Mr. ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
Cached News: